AstraZeneca heart drug results positive but not knock-out

March 16, 2015 9:31 AM

3 0

AstraZeneca heart drug results positive but not knock-out

LONDON (Reuters) - New clinical trial results with AstraZeneca's heart drug Brilinta are positive but bleeding risks suggest the company's sales force still has its work cut out to get the medicine widely adopted for long-term use.

AstraZeneca is relying on Brilinta, which it believes can sell $3.5 billion annually by 2023, to help offset a wave of patent losses on older drugs. The product was a central plank in its defense against a takeover bid by Pfizer last year.

Read more

To category page

Loading...